A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders

Leukemia and Lymphoma

Volumn 47, Issue 3, 2006, Pages 381-396

  Thiele, Juergen ^a   Kvasnicka, Hans M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Bone marrow features; Chronic idiopathic myelofibrosis; Chronic myeloid leukemia; Essential thrombocythemia; Fibrosis; Latent (initial) polycythemia; Polycythemia vera; Scoring of fibers

Indexed keywords

BIOLOGICAL MARKER; ERYTHROPOIETIN; HEMOGLOBIN; IMATINIB; JANUS KINASE 2; RETICULIN;

BONE MARROW EXAMINATION; CANCER STAGING; CANCER SURVIVAL; CELL CULTURE; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE COURSE; ERYTHROID CELL; ERYTHROPOIESIS; FIBER; GRANULOPOIESIS; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; MEDICAL DOCUMENTATION; MORPHOLOGY; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; POLYCYTHEMIA VERA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTHEMIA; VALIDITY; WORLD HEALTH ORGANIZATION;

CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, HEMORRHAGIC; WORLD HEALTH ORGANIZATION;

EID: 30844472030     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500331329     Document Type: Review

References (181)

1. Vardiman, J. (2003) Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases Semin Diagn Pathol, 20, pp. 154-179.
2. Vardiman, J and Pierre, R and Thiele, J and Imbert, M and Brunning, R and Flandrin, G. (2001) Chronic myeloproliferative disease. In WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. (pp. 9-38). Berlin: Springer.
3. Laszlo, J. (1975) Myeloproliferative disorders (MPD): Myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia Semin Hematol, 12, pp. 409-432.
4. Pearson, T. (1998) Diagnosis and classification of erythrocytoses and thrombocytoses Baillieres Clin Haematol, 11, pp. 695-720.
5. Berlin, N. (1975) Diagnosis and classification of the polycythemias Semin Hematol, 12, pp. 339-351.
6. Murphy, S and Peterson, P and Iland, H and Laszlo, J. (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment Semin Hematol, 34, pp. 29-39.
7. Murphy, S and Iland, H and Rosenthal, D and Laszlo, J. (1986) Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group Semin Hematol, 23, pp. 177-182.
8. Thiele, J and Kvasnicka, H. (2004) Prefibrotic chronic idiopathic myelofibrosis - a diagnostic enigma Acta Haematol, 111, pp. 155-159.
9. Buhr, T and Buesche, G and Choritz, H and Langer, F and Kreipe, H. (2003) Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens Am J Clin Pathol, 119, pp. 152-158.
10. Thiele, J and Imbert, M and Pierre, R and Vardiman, J and Brunning, R and Flandrin, G. (2001) Chronic idiopathic myelofibrosis. In WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. (pp. 35-38). Lyon: IARC Press.
11. Thiele, J and Kvasnicka, H and Boeltken, B and Zankovich, R and Diehl, V and Fischer, R. (1999) Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study Leukemia, 13, pp. 1741-1748.
12. Thiele, J and Zankovich, R and Steinberg, T and Fischer, R and Diehl, V. (1989) Agnogenic myeloid metaplasia (AMM) - correlation of bone marrow lesions with laboratory data: A longitudinal clinicopathological study on 114 patients Hematol Oncol, 7, pp. 327-343.
13. Barosi, G. (1999) Myelofibrosis with myeloid metaplasia. diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol, 17, pp. 2954-2970.
14. Tefferi, A. (2000) Myelofibrosis with myeloid metaplasia N Engl J Med, 342, pp. 1255-1265.
15. Barosi, G and Ambrosetti, A and Finelli, C and Grossi, A and Leoni, P and Liberato, N and (1999) The Italian Consensus Conference on diagnostic criteria for myelofibrosis with myeloid metaplasia Br J Haematol, 104, pp. 730-737.
16. Cervantes, F and Alvarez-Larran, A and Talarn, C and Gomez, M and Montserrat, E. (2002) Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: Actuarial probability, presenting characteristics and evolution in a series of 195 patients Br J Haematol, 118, pp. 786-790.
17. Dingli, D and Mesa, R and Tefferi, A. (2004) Myelofibrosis with myeloid metaplasia: New developments in pathogenesis and treatment Intern Med, 43, pp. 540-547.
18. Cervantes, F. (2005) Modern management of myelofibrosis Br J Haematol, 128, pp. 583-592.
19. Cervantes, F and Barosi, G and Demory, J and Reilly, J and Guarnone, R and Dupriez, B and (1998) Myelofibrosis with myeloid metaplasia in young individuals: Disease characteristics, prognostic factors and identification of risk groups Br J Haematol, 102, pp. 684-690.
20. Cervantes, F and Pereira, A and Esteve, J and Cobo, F and Rozman, C and Montserrat, E. (1998) The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades Eur J Haematol, 60, pp. 101-105.
21. Michiels, J and Thiele, J. (2002) Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia) Int J Hematol, 76, pp. 133-145.
22. Thiele, J and Kvasnicka, H and Zankovich, R and Diehl, V. (2000) Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis Haematologica, 85, pp. 1126-1134.
23. Imbert, M and Pierre, R and Thiele, J and Vardiman, J and Brunning, R and Flandrin, G. (2001) Essential thrombocythaemia. In WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. (pp. 39-41). Lyon: IARC Press.
24. Barbui, T and Barosi, G and Grossi, A and Gugliotta, L and Liberato, L and Marchetti, M and (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation Haematologica, 89, pp. 215-232.
25. Fruchtman, S. (2004) Treatment paradigms in the management of myeloproliferative disorders Semin Hematol, 41, pp. 18-22.
26. Finazzi, G and Barbui, T. (1999) Treatment of essential thrombocythemia with special emphasis on leukemogenic risk Ann Hematol, 78, pp. 389-392.
27. Harrison, C and Green, A. (2003) Essential thrombocythemia Hematol Oncol Clin North Am, 17, pp. 1175-1190.
28. Tefferi, A and Murphy, S. (2001) Current opinion in essential thrombocythemia: Pathogenesis, diagnosis, and management Blood Rev, 15, pp. 121-131.
29. Thiele, J and Kvasnicka, H. (2003) Chronic myeloproliferative disorders with thrombocythemia. a comparative study of two classification systems (PVSG, WHO) on 839 patients Ann Hematol, 82, pp. 148-152.
30. Michiels, J and Juvonen, E. (1997) Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group Semin Thromb Hemost, 23, pp. 339-347.
31. 9/1 be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages Br J Haematol, 100, pp. 15-23.
32. 9/l. Gruppo Italiano Malattie Mieloproliferative Croniche (GIMMC) Haematologica, 85, pp. 492-495.
33. Regev, A and Stark, P and Blickstein, D and Lahav, M. (1997) Thrombotic complications in essential thrombocythemia with relatively low platelet counts Am J Hematol, 56, pp. 168-172.
34. Pierre, R and Imbert, M and Thiele, J and Vardiman, J and Brunning, R and Flandrin, G. (2001) Polycythaemia vera. In WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. (pp. 32-38). Lyon: IARC Press.
35. Vardiman, J and Pierre, R and Thiele, J and Bain, B and Brunning, R and Harris, N and (2001) Chronic myelogenous leukemia. In WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. (pp. 20-26). Lyon: IARC Press.
36. Thiele, J and Kvasnicka, H and Facchetti, F and Franco, V and Van der Walt, J and Orazi, A. (2005) European consensus for grading of bone marrow fibrosis and assessment of cellularity Haematologica, 90, pp. 1128-1132.
37. Thiele, J and Kvasnicka, H and Diehl, V. (2005) Standardization of bone marrow features - does it work in hematopathology for histological discrimination of different disease patterns Histol Histopathol, 20, pp. 633-644.
38. The Benelux CML Study Group. (1998) Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML Study Group Blood, 91, pp. 2713-2721.
39. The Italian Cooperative Study Group on Chronic Myeloid Leukaemia. (1998) Long-term follow-up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia Blood, 92, pp. 1541-1548.
40. 1+ chronic myeloid leukemia: The value of early evaluation of the course of the disease. The Italian Cooperative Study Group on Chronic Myeloid Leukemia Ann Hematol, 63, pp. 307-314.
41. Kantarjian, H and Giles, F and O'Brien, S and Giralt, S and Talpaz, M. (2000) Therapeutic choices in younger patients with chronic myelogenous leukemia Cancer, 89, pp. 1647-1658.
42. Ohnishi, K and Tomonaga, M and Kamada, N and Onozawa, K and Kuramoto, A and Dohy, H and (1998) A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia The Kouseisho Leukemia Study Group. Leuk Res, 22, pp. 779-786.
43. Guilhot, F and Chastang, C and Michallet, M and Guerci, A and Harousseau, J and Maloisel, F and (1997) Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group N Engl J Med, 337, pp. 223-229.
44. Allan, N and Richards, S and Shepherd, P. (1995) UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet, 345, pp. 1392-1397.
45. Silver, R and Woolf, S and Hehlmann, R and Appelbaum, F and Anderson, J and Bennett, C and (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology Blood, 94, pp. 1517-1536.
46. Silver, R and Peterson, B and Szatrowski, T and Powell, B and Stock, W and Carroll, A and (2003) Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: Results from CALGB study 9013 Leuk Lymphoma, 44, pp. 39-48.
47. Cervantes, F and Hernandez-Boluda, J and Steegmann, J and Conde, E and Alvarez-Larran, A and Lopez-Jimenez, J and (2003) Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon. results and prognostic factors for response and progression-free survival in 150 patients Haematologica, 88, pp. 1117-1122.
48. O'Brien, S and Guilhot, F and Larson, R and Gathmann, I and Baccarani, M and Cervantes, F and (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med, 348, pp. 994-1004.
49. Cortes, J and Giles, F and O'Brien, S and Thomas, D and Albitar, M and Rios, M and (2003) Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders Cancer, 97, pp. 2760-2766.
50. Kantarjian, H and Talpaz, M and O'Brien, S and Giles, F and Rios, M and White, K and (2003) Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia Cancer, 97, pp. 2225-2228.
51. Kantarjian, H and O'Brien, S and Cortes, J and Giles, F and Shan, J and Rios, M and (2004) Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls Clin Cancer Res, 10, pp. 68-75.
52. Kantarjian, H and O'Brien, S and Cortes, J and Giles, F and Rios, M and Shan, J and (2003) Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data Cancer, 98, pp. 2636-2642.
53. Lorand-Metze, I and Vassallo, J and Souza, C. (1987) Histological and cytological heterogeneity of bone marrow in Philadelphia-positive chronic myelogenous leukaemia at diagnosis Br J Haematol, 67, pp. 45-49.
54. Bartl, R and Frisch, B and Wilmanns, W. (1993) Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD) Eur J Haematol, 50, pp. 41-52.
55. Georgii, A and Vykoupil, K and Buhr, T and Choritz, H and Dohler, U and Kaloutsi, V and (1990) Chronic myeloproliferative disorders in bone marrow biopsies Pathol Res Pract, 186, pp. 3-27.
56. Georgii, A and Buesche, G and Kreft, A. (1998) The histopathology of chronic myeloproliferative diseases Baillieres Clin Haematol, 11, pp. 721-749.
57. Dickstein, J and Vardiman, J. (1993) Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes Am J Clin Pathol, 99, pp. 513-525.
58. Lazzarino, M and Morra, E and Castello, A and Inverardi, D and Coci, A and Pagnucco, G and (1986) Myelofibrosis in chronic granulocytic leukaemia: Clinicopathologic correlations and prognostic significance Br J Haematol, 64, pp. 227-240.
59. Thiele, J and Kvasnicka, H and Schmitt-Graeff, A and Zirbes, T and Birnbaum, F and Kressmann, C and (2000) Bone marrow features and clinical findings in chronic myeloid leukemia-a comparative, multicenter, immunohistological and morphometric study on 614 patients Leuk Lymphoma, 36, pp. 295-308.
60. Thiele, J and Kvasnicka, H and Fischer, R. (1999) Bone marrow histopathology in chronic myelogenous leukemia (CML) - evaluation of distinctive features with clinical impact Histol Histopathol, 14, pp. 1241-1256.
61. Thiele, J and Thienel, C and Zankovich, R and Fischer, R. (1988) Prognostic features at diagnosis of chronic myeloid leukaemia with special emphasis on histological parameters Med Oncol Tumor Pharmacother, 5, pp. 49-60.
62. 1+ chronic myelogenous leukaemia Histopathology, 37, pp. 355-362.
63. Thiele, J and Wienhold, S and Zankovich, R and Fischer, R. (1990) A histomorphometric analysis of trephine biopsies of bone marrow from 65 patients with chronic myeloid leukemia Classification of patients into subgroups with different survival patterns. Anal Quant Cytol Histol, 12, pp. 103-116.
64. Hayhoe, F and Flemans, R and Cowling, D. (1979) Acquired lipidosis of marrow macrophages birefringent blue crystals and Gaucher-like cells, sea-blue histiocytes, and grey-green crystals. J Clin Pathol, 32, pp. 420-428.
65. Kelsey, P and Geary, C. (1988) Sea-blue histiocytes and Gaucher cells in bone marrow of patients with chronic myeloid leukaemia J Clin Pathol, 41, pp. 960-962.
66. Buesche, G and Majewski, H and Schlue, J and Delventhal, S and Baer-Henney, S and Vykoupil, K and (1997) Frequency of pseudo-Gaucher cells in diagnostic bone marrow biopsies from patients with Ph-positive chronic myeloid leukaemia Virchows Arch, 430, pp. 139-148.
67. Thiele, J and Kvasnicka, H and Titius, B and Parpert, U and Nebel, R and Zankovich, R and (1993) Histological features of prognostic significance in CML-an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow Ann Hematol, 66, pp. 291-302.
68. Thiele, J and Kvasnicka, H and Beelen, D and Wenzel, P and Koepke, M and Leder, L and (2000) Macrophages and their subpopulations following allogenic bone marrow transplantation for chronic myeloid leukaemia Virchows Arch, 437, pp. 160-166.
69. Buhr, T and Choritz, H and Georgii, A. (1992) The impact of megakaryocyte proliferation of the evolution of myelofibrosis. Histological follow-up study in 186 patients with chronic myeloid leukaemia Virchows Arch A Pathol Anat Histopathol, 420, pp. 473-478.
70. Thiele, J and Kvasnicka, H and Fischer, R and Diehl, V. (1997) Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: A concise update Leuk Lymphoma, 24, pp. 463-481.
71. 1+) chronic myelogenous leukemia: A multicenter trial J Clin Oncol, 19, pp. 2994-3009.
72. 1+ chronic myelogenous leukaemia - a multicentre study on 495 patients Br J Haematol, 112, pp. 727-739.
73. Thiele, J and Kvasnicka, H and Zirbes, T and Flucke, U and Niederle, N and Leder, L and (1998) Impact of clinical and morphological variables in classification and regression tree-based survival (CART) analysis of CML with special emphasis on dynamic features Eur J Haematol, 60, pp. 35-46.
74. Thiele, J and Kvasnicka, H and Fischer, R. (1999) Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification Ann Hematol, 78, pp. 495-506.
75. Buesche, G and Georgii, A and Duensing, A and Schmeil, A and Schlue, J and Kreipe, H. (2003) Evaluating the Volume ratio of bone marrow affected by fibrosis. a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia Hum Pathol, 34, pp. 391-401.
76. Buhr, T and Georgii, A and Choritz, H. (1993) Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification Pathol Res Pract, 189, pp. 121-132.
77. Gralnick, H and Harbor, J and Vogel, C. (1971) Myelofibrosis in chronic granulocytic leukemia Blood, 37, pp. 152-162.
78. Dekmezian, R and Kantarjian, H and Keating, M and Talpaz, M and McCredie, K and Freireich, E. (1987) The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia Cancer, 59, pp. 1739-1743.
79. Clough, V and Geary, C and Hashmi, K and Davson, J and Knowlson, T. (1979) Myelofibrosis in chronic granulocytic leukaemia Br J Haematol, 42, pp. 515-526.
80. Buesche, G and Hehlmann, R and Hecker, H and Heimpel, H and Heinze, B and Schmeil, A and (2003) Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia-prospective long-term results from a randomized-controlled trial Leukemia, 17, pp. 2444-2453.
81. Thiele, J and Hoefer, M and Kvasnicka, H and Bertsch, H and Zankovich, R and Fischer, R. (1993) Erythropoiesis in CML-immunomorphometric quantification, PCNA-reactivity, and influence on survival Hematol Pathol, 7, pp. 239-249.
82. Hasford, J and Pfirrmann, M and Hehlmann, R and Allan, N and Baccarani, M and Kluin-Nelemans, J and (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group J Natl Cancer Inst, 90, pp. 850-858.
83. Kantarjian, H and Keating, M and Smith, T and Talpaz, M and McCredie, K. (1990) Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia Am J Med, 88, pp. 1-8.
84. Lugli, A and Ebnoether, M and Cogliatti, S and Gratwohl, A and Passweg, J and Hess, U and (2005) Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia Hum Pathol, 36, pp. 91-100.
85. Kantarjian, H and Bueso-Ramos, C and Talpaz, M and O'Brien, S and Giles, F and Rios, M and (2005) The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy Leuk Lymphoma, 46, pp. 993-997.
86. Thiele, J and Kvasnicka, H and Beelen, D and Zirbes, T and Jung, F and Reske, D and (2000) Relevance and dynamics of myelofibrosis regarding hematopoietic reconstitution after allogeneic bone marrow transplantation in chronic myelogenous leukemia - a single center experience on 160 patients Bone Marrow Transplant, 26, pp. 275-281.
87. Thiele, J and Kvasnicka, H and Beelen, D and Flucke, U and Spoer, C and Paperno, S and (2001) Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: An immunohistochemical study of 127 patients Mod Pathol, 14, pp. 129-138.
88. Thiele, J and Kvasnicka, H and Beelen, D and Leder, L and Schaefer, U. (2001) Bone marrow engraftment: Histopathology of hematopoietic reconstitution following allogeneic transplantation in CML patients Histol Histopathol, 16, pp. 213-226.
89. Thiele, J and Fischer, R. (1991) Megakaryocytopoiesis in haematological disorders: Diagnostic features of bone marrow biopsies. An overview Virchows Arch A Pathol Anat Histopathol, 418, pp. 87-97
90. Thiele, J and Titius, B and Kopsidis, C and Fischer, R. (1992) Atypical micromegakaryocytes, promegakaryoblasts and megakaryoblasts. a critical evaluation by immunohistochemistry, cytochemistry and morphometry of bone marrow trephines in chronic myeloid leukemia and myelodysplastic syndromes Virchows Arch B Cell Pathol Incl Mol Pathol, 62, pp. 275-282.
91. Nafe, R and Georgii, A and Kaloutsi, V and Fritsch, R and Choritz, H. (1991) Planimetric analysis of megakaryocytes in the four main groups of chronic myeloproliferative disorders Virchows Arch B Cell Pathol Incl Mol Pathol, 61, pp. 111-116.
92. Thiele, J and Kvasnicka, H and Schmitt-Graeff, A and Diehl, V and Niederle, N and Schaefer, H. (2001) Bone marrow histopathology predicting blast crisis in chronic myeloid leukemia Acta Haematol, 105, pp. 244-246.
93. Bacher, U and Kern, W and Schnittger, S and Hiddemann, W and Schoch, C and Haferlach, T. (2005) Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia Leuk Lymphoma, 46, pp. 357-366.
94. Spivak, J. (2002) Polycythemia vera: Myths, mechanisms, and management Blood, 100, pp. 4272-4290.
95. Tefferi, A. (2003) A contemporary approach to the diagnosis and management of polycythemia vera Curr Hematol Rep, 2, pp. 237-241.
96. Bilgrami, S and Greenberg, B. (1995) Polycythemia rubra vera Semin Oncol, 22, pp. 307-326.
97. Murphy, S. (1999) Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia Semin Hematol, 36, pp. 9-13.
98. McMullin, M and Bareford, D and Campbell, P and Green, A and Harrison, C and Hunt, B and (2005) Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis Br J Haematol, 130, pp. 174-195.
99. Streiff, M and Smith, B and Spivak, J. (2002) The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: A survey of American Society of Hematology members' practice patterns Blood, 99, pp. 1144-1149.
100. Ellis, J and Silver, R and Coleman, M and Geller, S. (1975) The bone marrow in polycythemia vera Semin Hematol, 12, pp. 433-444.
101. Ellis, J and Peterson, P and Geller, S and Rappaport, H. (1986) Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies Semin Hematol, 23, pp. 144-155.
102. Ellis, J and Peterson, P. (1979) The bone marrow in polycythemia vera Pathol Annu, 1, pp. 383-403.
103. Iland, H and Laszlo, J and Case, D, Jr and Murphy, S and Reichert, T and Tso, C and (1987) Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis Am J Hematol, 25, pp. 191-201.
104. Georgii, A and Buhr, T and Buesche, G and Kreft, A and Choritz, H. (1996) Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies Leuk Lymphoma, 22(Suppl 1), pp. 15-29.
105. Thiele, J and Kvasnicka, H and Diehl, V. (2005) Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia Acta Haematol, 113, pp. 213-219.
106. Thiele, J and Kvasnicka, H and Muehlhausen, K and Walter, S and Zankovich, R and Diehl, V. (2001) Polycythemia rubra vera vs. secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients Pathol Res Pract, 197, pp. 77-84.
107. Thiele, J and Kvasnicka, H and Zankovich, R and Diehl, V. (2001) The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias Haematologica, 86, pp. 368-374.
108. Thiele, J and Kvasnicka, H and Diehl, V. (2005) Bone marrow features of diagnostic impact in erythrocytosis Ann Hematol, 84, pp. 362-367.
109. Liu, E and Jelinek, J and Pastore, Y and Guan, Y and Prchal, J and Prchal, J. (2003) Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin Blood, 101, pp. 3294-3301.
110. Messinezy, M and Pearson, T. (1999) The classification and diagnostic criteria of the erythrocytoses (polycythaemias) Clin Lab Haematol, 21, pp. 309-316.
111. Kralovics, R and Buser, A and Teo, S and Coers, J and Tichelli, A and van der Maas, A and (2003) Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders Blood, 102, pp. 1869-1871.
112. Birgegard, G and Wide, L. (1992) Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment Br J Haematol, 81, pp. 603-606.
113. Messinezy, M and Westwood, N and Woodcock, S and Strong, R and Pearson, T. (1995) Low serum erythropoietin - a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels Clin Lab Haematol, 17, pp. 217-220.
114. Carneskog, J and Kutti, J and Wadenvik, H and Lundberg, P and Lindstedt, G. (1998) Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia Eur J Haematol, 60, pp. 278-282.
115. Mossuz, P and Girodon, F and Donnard, M and Latger-Cannard, V and Dobo, I and Boiret, N and (2004) Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis Haematologica, 89, pp. 1194-1198.
116. Messinezy, M and Westwood, N and El-Hemaidi, I and Marsden, J and Sherwood, R and Pearson, T. (2002) Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia Br J Haematol, 117, pp. 47-53.
117. Andreasson, B and Carneskog, J and Lindstedt, G and Lundberg, P and Swolin, B and Wadenvik, H and (2000) Plasma erythropoietin concentrations in polycythaemia vera with special reference to myelosuppressive therapy Leuk Lymphoma, 37, pp. 189-195.
118. Girodon, F and Hermouet, S and Dobo, I and Mossuz, P. (2003) Serum erythropoietin values and endogenous erythroid colony growth in erythrocytoses and essential thrombocythaemia Br J Haematol, 120, pp. 171.
119. Shih, L and Lee, C and See, L and Ou, Y and Dunn, P and Wang, P and (1998) In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia Eur J Clin Invest, 28, pp. 569-576.
120. Eridani, S and Sawyer, B and Pearson, T. (1987) Patterns of in vitro BFU-E proliferation in different forms of polycythaemia and in thrombocythaemia Eur J Haematol, 38, pp. 363-369.
121. Lemoine, F and Najman, A and Baillou, C and Stachowiak, J and Boffa, G and Aegerter, P and (1986) A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia Blood, 68, pp. 996-1002.
122. Partanen, S and Juvonen, E and Ikkala, E and Ruutu, T. (1989) Spontaneous erythroid colony formation in the differential diagnosis of erythrocytosis Eur J Haematol, 42, pp. 327-330.
123. Westwood, N and Dudley, J and Sawyer, B and Messinezy, M and Pearson, T. (1993) Primary polycythaemia: Diagnosis by non-conventional positive criteria Eur J Haematol, 51, pp. 228-232.
124. Dobo, I and Donnard, M and Girodon, F and Mossuz, P and Boiret, N and Boukhari, R and (2004) Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera Hematol J, 5, pp. 161-167.
125. Weinberg, R and Worsley, A and Gilbert, H and Cuttner, J and Berk, P and Alter, B. (1989) Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: Only polycythemia vera has endogenous colonies Leuk Res, 13, pp. 331-338.
126. Thiele, J and Kvasnicka, H. (2005) Diagnostic impact of bone marrow histopathology in polycythemia vera (PV) Histol Histopathol, 20, pp. 317-328.
127. Gruppo Italiano Studio Policitemia. (1995) Polycythemia vera: The natural history of 1213 patients followed for 20 years Ann Intern Med, 123, pp. 656-664.
128. Najean, Y and Triebel, F and Dresch, C. (1981) Pure erythrocytosis. reappraisal of a study of 51 cases Am J Hematol, 10, pp. 129-136.
129. Pearson, T and Wetherley-Mein, G. (1979) The course and complications of idiopathic erythrocytosis Clin Lab Haematol, 1, pp. 189-196.
130. Ruggeri, M and Tosetto, A and Frezzato, M and Rodeghiero, F. (2003) The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis Ann Intern Med, 139, pp. 470-475.
131. Michiels, J and Barbui, T and Finazzi, G and Fuchtman, S and Kutti, J and Rain, J and (2000) Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG Leuk Lymphoma, 36, pp. 239-253.
132. Jantunen, R and Juvonen, E and Ikkala, E and Oksanen, K and Anttila, P and Ruutu, T. (1999) Development of erythrocytosis in the course of essential thrombocythemia Ann Hematol, 78, pp. 219-222.
133. Shih, L and Lee, C. (1994) Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay Blood, 83, pp. 744-748.
134. Griesshammer, M and Klippel, S and Strunck, E and Temerinac, S and Mohr, U and Heimpel, H and (2004) PRV-1 mRNA expression discriminates two types of essential thrombocythemia Ann Hematol, 83, pp. 364-370.
135. Griesshammer, M and Kubanek, B and Beneke, H and Heimpel, H and Bangerter, M and Bergmann, L and (2000) Serum erythropoietin and thrombopoietin levels in patients with essential thrombocythaemia Leuk Lymphoma, 36, pp. 533-538.
136. Baxter, E and Scott, L and Campbell, P and East, C and Fourouclas, N and Swanton, S and (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet, 365, pp. 1054-1061.
137. Kralovics, R and Passamonti, F and Buser, A and Teo, S and Tiedt, R and Passweg, J and (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med, 352, pp. 1779-1790.
138. James, C and Ugo, V and Le Couedic, J and Staerk, J and Delhommeau, F and Lacout, C and (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature, 434, pp. 1144-1148.
139. Jones, A and Kreil, S and Zoi, K and Waghorn, K and Curtis, C and Zhang, L and Score, J and (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Blood, 106, pp. 2162-2168.
140. Zhao, R and Xing, S and Li, Z and Fu, X and Li, Q and Krantz, S and (2005) Identification of an acquired JAK2 mutation in polycythemia vera J Biol Chem, 280, pp. 22788-22792.
141. Levine, R and Wadleigh, M and Cools, J and Ebert, B and Wernig, G and Huntly, B and (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell, 7, pp. 387-397.
142. Goerttler, P and Steimle, C and Marz, E and Johansson, P and Andreasson, B and Griesshammer, M and (2005) The Jak2V617F, mutation PRV-1 overexpression and EEC formation define a similar cohort of MPD patients Blood, 106, pp. 2862-2864.
143. Ugo, V and Marzac, C and Teyssandier, I and Larbret, F and Lecluse, Y and Debili, N and (2005) Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera Exp Hematol, 32, pp. 179-187.
144. Arcasoy, M and Harris, K and Forget, B. (1999) A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation Exp Hematol, 27, pp. 63-74.
145. Juvonen, E and Ikkala, E and Oksanen, K and Ruutu, T. (1993) Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: Diagnostic value and correlation to complications Br J Haematol, 83, pp. 192-197.
146. Jantunen, R and Juvonen, E and Ikkala, E and Oksanen, K and Anttila, P and Hormila, P and (1998) Essential thrombocythemia at diagnosis: Causes of diagnostic evaluation and presence of positive diagnostic findings Ann Hematol, 77, pp. 101-106.
147. Steensma, D and Dewald, G and Lasho, T and Powell, H and McClure, R and Levine, R and (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'typical' myeloproliferative disorders and the myelodysplastic syndrome Blood, 106, pp. 1207-1209.
148. Thiele, J and Kvasnicka, H and Zankovich, R and Diehl, V. (2001) Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis Ann Hematol, 80, pp. 160-165.
149. Thiele, J and Kvasnicka, H and Zankovich, R and Diehl, V. (2002) Early stage idiopathic (primary) myelofibrosis - current issues of diagnostic features Leuk Lymphoma, 43, pp. 1035-1041.
150. Thiele, J and Kvasnicka, H. (2005) Hematopathological findings in chronic idiopathic myelofibrosis (CIMF) Semin Oncol, 32, pp. 380-394.
151. Wolf, B and Neiman, R. (1985) Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly Blood, 65, pp. 803-809.
152. Rupoli, S and Da Lio, L and Sisti, S and Campanati, G and Salvi, A and Brianzoni, M and (1994) Primary myelofibrosis: A detailed statistical analysis of the clinicopathological variables influencing survival Ann Hematol, 68, pp. 205-212.
153. Dupriez, B and Morel, P and Demory, J and Lai, J and Simon, M and Plantier, I and (1996) Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system Blood, 88, pp. 1013-1018.
154. Reilly, J. (1997) Idiopathic myelofibrosis. pathogenesis, natural history and management Blood Rev, 11, pp. 233-242.
155. Visani, G and Finelli, C and Castelli, U and Petti, M and Ricci, P and Vianelli, N and (1990) Myelofibrosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients Br J Haematol, 75, pp. 4-9.
156. Mesa, R and Hanson, C and Rajkumar, S and Schroeder, G and Tefferi, A. (2000) Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia Blood, 96, pp. 3374-3380.
157. Thiele, J and Hoeppner, B and Zankovich, R and Fischer, R. (1989) Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/ -sclerosis (agnogenic myeloid metaplasia) - correlations between clinical and morphological features Virchows Arch A Pathol Anat Histopathol, 415, pp. 191-202.
158. Thiele, J and Kvasnicka, H and Schmitt-Graeff, A and Diehl, V. (2003) Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: A follow-up study on 309 patients Leuk Lymphoma, 44, pp. 949-953.
159. Thiele, J and Chen, Y and Kvasnicka, H and Diehl, V and Fischer, R. (1994) Evolution of fibro-osteosclerotic bone marrow lesions in primary (idiopathic) osteomyelofibrosis - a histomorphometric study on sequential trephine biopsies Leuk Lymphoma, 14, pp. 163-169.
160. Kreft, A and Buche, G and Ghalibafian, M and Buhr, T and Fischer, T and Kirkpatrick, C. (2005) The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: A retrospective evaluation of sequential bone marrow biopsies Acta Haematol, 113, pp. 137-143.
161. Harrison, C. (2005) Essential thrombocythaemia: Challenges and evidence-based management Br J Haematol, 130, pp. 153-165.
162. Thiele, J and Kvasnicka, H and Werden, C and Zankovich, R and Diehl, V and Fischer, R. (1996) Idiopathic primary osteo-myelofibrosis: A clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact Leuk Lymphoma, 22, pp. 303-317.
163. Thiele, J and Kvasnicka, H and Diehl, V and Fischer, R and Michiels, J. (1999) Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies Leuk Lymphoma, 33, pp. 207-218.
164. Thiele, J and Kvasnicka, H. (2003) Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features - a clinicopathological study on 272 patients Histol Histopathol, 18, pp. 93-102.
165. Thiele, J and Schneider, G and Hoeppner, B and Wienhold, S and Zankovich, R and Fischer, R. (1988) Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis - features of significance for the diagnosis of primary (essential) thrombocythaemia Virchows Arch A Pathol Anat Histopathol, 413, pp. 407-417.
166. Griesshammer, M and Bangerter, M and Sauer, T and Wennauer, R and Bergmann, L and Heimpel, H. (1999) Aetiology and clinical significance of thrombocytosis: Analysis of 732 patients with an elevated platelet count J Intern Med, 245, pp. 295-300.
167. Santhosh-Kumar, C and Yohannan, M and Higgy, K and al-Mashhadani, S. (1991) Thrombocytosis in adults. analysis of 777 patients J Intern Med, 229, pp. 493-495.
168. Kutti, J and Wadenvik, H. (1996) Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis Leuk Lymphoma, 22(Suppl 1), pp. 41-45.
169. Schafer, A. (2001) Thrombocytosis and thrombocythemia Blood Rev, 15, pp. 159-166.
170. Schafer, A. (2004) Thrombocytosis N Engl J Med, 350, pp. 1211-1219.
171. Chait, Y and Condat, B and Cazals-Hatem, D and Rufat, P and Atmani, S and Chaoui, D and (2005) Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis Br J Haematol, 129, pp. 553-560.
172. Florena, A and Tripodo, C and Iannitto, E and Porcasi, R and Ingrao, S and Franco, V. (2004) Value of bone marrow biopsy in the diagnosis of essential thrombocythemia Haematologica, 89, pp. 911-919.
173. Bauermeister, D. (1971) Quantitation of bone marrow reticulin - a normal range Am J Clin Pathol, 56, pp. 24-31.
174. Manoharan, A and Horsley, R and Pitney, W. (1979) The reticulin content of bone marrow in acute leukaemia in adults Br J Haematol, 43, pp. 185-190.
175. Beckman, E and Brown, A, Jr. (1990) Normal reticulin level in iliac bone marrow Arch Pathol Lab Med, 114, pp. 1241-1243.
176. Harrison, C and Campbell, P and Buck, G and Wheatley, K and East, C and Bareford, D and (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia N Engl J Med, 353, pp. 33-45.
177. Thiele, J and Kvasnicka, H and Schmitt-Graeff, A and Zankovich, R and Diehl, V. (2002) Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients Am J Hematol, 70, pp. 283-291.
178. Cervantes, F and Tassies, D and Salgado, C and Rovira, M and Pereira, A and Rozman, C. (1991) Acute transformation in nonleukemic chronic myeloproliferative disorders. actuarial probability and main characteristics in a series of 218 patients Acta Haematol, 85, pp. 124-127.
179. Emilia, G and Sacchi, S and Temperani, P and Longo, R and Vecchi, A. (1993) Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis Leuk Lymphoma, 9, pp. 423-426.
180. Frei-Lahr, D and Barton, J and Hoffman, R and Burkett, L and Prchal, J. (1984) Blastic transformation of essential thrombocythemia: Dual expression of myelomonoblastic/megakaryoblastic phenotypes Blood, 63, pp. 866-872.
181. Radaelli, F and Mazza, R and Curioni, E and Ciani, A and Pomati, M and Maiolo, A. (2002) Acute megakaryocytic leukemia in essential thrombocythemia: An unusual evolution Eur J Haematol, 69, pp. 108-111.